Literature DB >> 19879857

Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1.

Bo Hong1, Vivian W Y Lui, Edwin P Hui, Yiling Lu, Horasis S Y Leung, Elaine Y L Wong, Suk-Hang Cheng, Margaret H L Ng, Gordon B Mills, Anthony T C Chan.   

Abstract

YC-1 has recently been demonstrated to have potent anti-invasion and anti-metastatic activity in several cancer models, in addition to its anti-proliferation activity. However, the mechanism underlying its anti-invasion/anti-metastatic activity is largely unknown. Nasopharyngeal carcinoma (NPC) is a highly metastatic head and neck cancer in Southeast Asia. Here, we demonstrated that YC-1 inhibited invasiveness and proliferation of NPC cells, with the latter being accompanied by PARP cleavage, S-phase arrest and activation of Chk1/Chk2. We aimed at identifying novel anti-invasion mechanisms of YC-1 in NPC by a functional proteomic platform, the reverse phase protein array (RPPA). Our study revealed for the first time that multiple invasion-related signaling proteins (beta-catenin, caveolin, Src and EGFR), as well as several growth-related proteins (AMPKalpha, phospho-acetyl-CoA carboxylase (p-ACC), HER-2 and mTOR), which were previously un-described signaling proteins altered by YC-1, were found to be down-modulated by YC-1 in NPC cells. We hypothesized that YC-1-mediated downregulation of these invasion proteins contributed to its anti-invasion activity in NPC cells. Overexpression of EGFR, activated Src or caveolin, but not beta-catenin reversed the inhibitory effects of YC-1 on NPC cell invasion, with EGFR and activated Src having additional effects on rescuing NPC cells from YC-1-mediated growth inhibition. In summary, we have identified several novel anti-invasion mechanisms of YC-1 that could impact NPC, and possibly other cancers as well. Copyright 2009. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879857     DOI: 10.1016/j.bcp.2009.10.021

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

2.  Models for Predicting Stage in Head and Neck Squamous Cell Carcinoma Using Proteomic and Transcriptomic Data.

Authors:  Chanchala D Kaddi; May D Wang
Journal:  IEEE J Biomed Health Inform       Date:  2015-10-08       Impact factor: 5.772

3.  YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.

Authors:  Ling-Chu Chang; Hui-Yi Lin; Meng-Tung Tsai; Ruey-Hwang Chou; Fang-Yu Lee; Che-Ming Teng; Min-Tsang Hsieh; Hsin-Yi Hung; Li-Jiau Huang; Yung-Luen Yu; Sheng-Chu Kuo
Journal:  Br J Pharmacol       Date:  2014-07-25       Impact factor: 8.739

4.  YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition.

Authors:  Ying Cheng; Wei Li; Ying Liu; Huan-Chen Cheng; Jun Ma; Lin Qiu
Journal:  Chin J Cancer       Date:  2012-04-13

5.  Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues.

Authors:  K Malinowsky; C Wolff; S Gündisch; D Berg; Kf Becker
Journal:  J Cancer       Date:  2010-12-19       Impact factor: 4.207

Review 6.  Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use.

Authors:  Stefanie Boellner; Karl-Friedrich Becker
Journal:  Microarrays (Basel)       Date:  2015-03-24

7.  YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells.

Authors:  Miau-Rong Lee; Chingju Lin; Chi-Cheng Lu; Sheng-Chu Kuo; Je-Wei Tsao; Yu-Ning Juan; Hong-Yi Chiu; Fang-Yu Lee; Jai-Sing Yang; Fuu-Jen Tsai
Journal:  Biomedicine (Taipei)       Date:  2017-06-14

Review 8.  Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development.

Authors:  Mu-Tai Liu; Mu-Kuan Chen; Chia-Chun Huang; Chao-Yuan Huang
Journal:  World J Oncol       Date:  2015-02-14

9.  PAX2 Expression in Ovarian Cancer.

Authors:  Huijuan Song; Suet-Yan Kwan; Daisy I Izaguirre; Zhifei Zu; Yvonne T Tsang; Celestine S Tung; Erin R King; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Int J Mol Sci       Date:  2013-03-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.